Optimized NAMPT Inhibitors Enable Highly Effective ADCs for Liquid and Solid Tumors, Achieving Complete Regressions in Preclinical Models

ACS Bio & Med Chem Au USA

Overview

This publication details the development of next-generation NAMPT inhibitors as ADC payloads through physicochemical and metabolic optimization. When conjugated to anti-CD30, anti-HER2, or anti-TROP2 antibodies, the optimized inhibitors demonstrated durable responses and complete regressions across various tumor models. This research strongly supports NAMPT inhibition as a promising mode of action for developing next-generation antibody-drug conjugates, offering a new avenue for targeted cancer therapies.

In Depth

Key Findings

A study published in ‘ACS Bio & Med Chem Au’ demonstrates that physicochemical and metabolic optimization of NAMPT (nicotinamide adenine dinucleotide phosphoribosyltransferase) inhibitors can enable their development as highly effective antibody-drug conjugate (ADC) payloads for both liquid and solid tumors. ADCs armed with these optimized NAMPT inhibitors, when conjugated to anti-CD30, anti-HER2, or anti-TROP2 antibodies, achieved durable responses and significant complete regressions in various preclinical tumor models.

Technical / Clinical Details

NAMPT is a rate-limiting enzyme in the cellular NAD+ biosynthesis pathway and is often overexpressed in many cancers. Cancer cells’ high dependency on NAMPT makes its inhibition a potent anti-tumor strategy. However, systemic NAMPT inhibition can lead to toxicity in normal tissues, particularly those dependent on NAD+. This research involved exquisite optimization of the NAMPT inhibitors’ physicochemical properties (e.g., solubility, membrane permeability) and metabolic stability to enhance their suitability as ADC payloads. This design ensures that the payload retains its activity upon release within the tumor microenvironment while minimizing systemic toxicity. ADCs armed with these optimized NAMPT inhibitors exhibited potent in vitro cytotoxic activity and dose-dependent tumor growth inhibition in in vivo xenograft models (e.g., lymphoma, breast cancer, lung cancer models), with some models showing complete tumor regression. These results underscore the promise of NAMPT inhibitors as ADC payloads, balancing potent efficacy with an improved safety profile.

Background & Context

Antibody-drug conjugates have garnered significant attention as targeted cancer therapeutics, but their success hinges on the potency of the chosen payload, the stability of the linker, and the appropriate selection of the target antigen. While existing ADC payloads (e.g., tubulin inhibitors, DNA-damaging agents) are powerful, challenges arise from the emergence of resistance mechanisms and limitations in specific tumor types. Developing payloads with novel mechanisms of action, such as NAMPT inhibition, offers the potential to provide new therapeutic options for patients whose cancers do not respond to existing treatments. This research highlights the importance of payload diversification in next-generation ADC development, contributing to advancements in treating cancers with high unmet medical needs.

Strategic Significance & Outlook

NAMPT inhibitor-based ADCs, given their potent anti-tumor activity and potential for complete regressions demonstrated in preclinical data, hold significant promise for future clinical development. Specifically, these new ADC classes could be effective treatment options for tumors resistant to existing ADC therapies or those with high NAMPT expression. The findings of this study expand the design principles of ADC platforms and will accelerate the discovery and optimization of novel payloads. If these ADC candidates advance to clinical trials and prove safe and effective in humans, they could significantly transform treatment paradigms for both liquid and solid tumors. Investors are keen on innovative approaches like this that complement existing ADC technologies and open up new market opportunities in oncology.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime